Annapurna Das appointed as new General Manager for Takeda’s India operations

With over 20 years of experience, Das to lead initiatives in enhancing patient access to innovative medicines and strengthening collaborations in the Indian healthcare sector

New Delhi: Takeda Biopharmaceuticals India has appointed Annapurna Das as the General Manager for its India operations.
Effective as of May 16, 2024, Das will spearhead the company’s initiatives in India, focusing on enhancing patient access to Takeda’s innovative medicines and vaccines and fostering key collaborations within the burgeoning domestic healthcare and pharmaceutical sectors.
With over two decades of experience in the pharmaceutical and biotechnology industries across India and Southeast Asia, Das has held pivotal roles at renowned multinational healthcare companies such as Miltenyi Biotec, Sanofi, GSK, MSD, Pfizer, and Organon. Her expertise spans sales, marketing, corporate strategy, and business development, particularly in the pharma and vaccines sectors.
“I am truly honoured to be entrusted with this responsibility by Takeda,” said Annapurna Das. India is one of the key countries for us, given its diverse population and the significant healthcare challenges. We are fully committed to serving patients in India by providing them with greater access to our innovative medicines and vaccines, ensuring they receive the best possible care. I look forward to working closely with our stakeholders and partners to strengthen our commitment in India while positively impacting the lives of patients across the country.”
Dion Warren, Area Head of India and Southeast Asia at Takeda expressed enthusiasm about Das’s appointment. “We are excited to welcome Annapurna to Takeda. Her vast experience and dedication to patient-focused solutions will fuel our continued success and growth in India. With her strategic leadership, we strive to positively impact patients’ lives with Takeda’s innovative healthcare solutions and partnerships to broaden sustainable and equitable access to medicines and vaccines. Annapurna’s alignment with Takeda’s purpose and values reinforces our commitment to fostering a diverse and inclusive workplace, enabling us to create long-term value for patients and society. I am excited to partner with her to build on our strong foundation and take us to the next level of growth in India.”
Takeda India, part of the Japan-headquartered Takeda Pharmaceutical Company Ltd, specializes in areas including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, and oncology. The company aims to leverage Das’s leadership to expand its footprint and enhance its impact on the Indian healthcare landscape.